Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.19, $0.16 better than the analyst estimate of $0.03. Revenue for the quarter came in at $69.6 million versus the consensus estimate of $67.8 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.